DOCSLIB.ORG

Who Expert Committee on Specifications for Pharmaceutical Preparations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Who Expert Committee on Specifications for Pharmaceutical Preparations WHO Technical Report Series 948 SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS SPECIFICATIONS The Expert Committee on Specifi cations for Pharmaceutical WHO EXPERT COMMITTEE Preparations works towards clear, independent and practical standards and guidelines for the quality assurance of medicines. ON SPECIFICATIONS FOR Standards are developed by the Committee through worldwide consultation and an international consensus-building process. PHARMACEUTICAL PREPARATIONS The following new standards and guidelines were adopted and recommended for use: the current list of available International Chemical Reference Substances and International Infrared Reference Spectra; guidelines on the active pharmaceutical ingredient master fi le procedure; the procedure for assessing the acceptability of male latex condoms and that of intrauterine devices for purchase by United Nations and other agencies; and a review of International Nonproprietary Names for biological and biotechnological substances. Forty-second report WHO Technical Report Series — 948 WHO Technical ISBN 9789241209489 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health. One of WHO’s constitutional functions is to provide objective and reliable information and advice in the The International Pharmacopoeia, fourth edition. fi eld of human health, a responsibility that it fulfi ls in part through its extensive Volume 1: general notices; monographs for pharmaceutical substances (A–O) programme of publications. The Organization seeks through its publications to Volume 2: monographs for pharmaceutical substances (P–Z); monographs for dosage forms support national health strategies and address the most pressing public health and radiopharmaceutical preparations; methods of analysis; reagents. concerns of populations around the world. To respond to the needs of Member 2006 (1500 pages), also available in CD-ROM format and on line States at all levels of development, WHO publishes practical manuals, handbooks First supplement: general notices; monographs for pharmaceutical substances; monographs and training material for specifi c categories of health workers; internationally for dosage forms; general and specifi c monographs; methods of analysis; International applicable guidelines and standards; reviews and analyses of health policies, Chemical Reference Substances; International Infrared Reference Spectra; reagents, test programmes and research; and state-of-the-art consensus reports that offer solutions and volumetric solutions, 2008 (in press) technical advice and recommendations for decision-makers. These books are closely tied to the Organization’s priority activities, encompassing disease Basic tests for drugs: pharmaceutical substances, prevention and control, the development of equitable health systems based medicinal plant materials and dosage forms on primary health care, and health promotion for individuals and communities. 1998 (94 pages) Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of Basic tests for pharmaceutical dosage forms all WHO’s Member countries and the collaboration of world leaders in public 1991 (134 pages) health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures Quality Assurance of Pharmaceuticals: a compendium of guidelines and related materials the broad international distribution of its publications and encourages their Volume 1: 1997 (244 pages) translation and adaptation. By helping to promote and protect health and Volume 2: Good manufacturing practices and inspection. prevent and control disease throughout the world, WHO’s books contribute to 2nd updated edition, 2007 (in press) achieving the Organization’s principal objective — the attainment by all people Also available on: WHO training modules on GMP. A resource and study pack for trainers, of the highest possible level of health. 2007 (CD-ROM) WHO Expert Committee on Specifi cations for Pharmaceutical Preparations Forty-fi rst report. The WHO Technical Report Series makes available the fi ndings of various WHO Technical Report Series, No. 943, 2007 (156 pages) international groups of experts that provide WHO with the latest scientifi c and technical advice on a broad range of medical and public health subjects. International Nonproprietary Names (INN) for pharmaceutical substances Members of such expert groups serve without remuneration in their personal Cumulative List no. 12 capacities rather than as representatives of governments or other bodies; their 2007 (available in CD-ROM format only) views do not necessarily refl ect the decisions or the stated policy of WHO. An annual subscription to this series, comprising about six such reports, costs The use of essential medicines CHF 168.00/US$ 151.00 (CHF 128.40/US$ 115.00 in developing countries). Report of the WHO Expert Committee (including the 15th Model List of Essential Medicines). For further information, please contact: WHO Press, World Health Organization, WHO Technical Report Series, No. 946, 2007 (163 pages). First WHO Model List of 20 avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; Essential Medicines for Children (http://www.who.int/childmedicines/en/index.html) fax: +41 22 791 4857; e-mail: [email protected]; order on line: http://www. who.int/bookorders). WHO Expert Committee on Biological Standardization Fifty-fi fth report. WHO Technical Report Series, No. 941, 2008 (290 pages) (in press) Further information on these and other WHO publications can be obtained from WHO Press, World Health Organization, 1211 Geneva 27, Switzerland. This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization WHO Technical Report Series 948 WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS Forty-second report Geneva 2007 WHO Library Cataloguing-in-Publication DataPublications of the World Health Organization enjoy copyright protection in accordance with the WHO Library Cataloguing-in-Publication Data Forty-second report of the WHO Expert Committee on Specifi cations for Pharmaceutical Preparations. (WHO Technical Report Series, No. 948) 1. Pharmaceutical preparations - standards. 2. Technology, Pharmaceuticals - standards. 3. Drug industry - legislation. 4. Quality control. I. World Health Organization. II. Series. ISBN 978 92 4 120948 9 (NLM classifi cation: QV 771) ISSN 0512-3054 © World Health Organization 2008 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specifi c companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization. Typeset in Switzerland Printed in Switzerland Contents 1. Introduction 1 2. General policy 8 2.1 Collaboration with international organizations and agencies 8 2.2 Cross-cutting pharmaceuticals — quality assurance issues 13 2.3 Essential medicines for children 17 2.4 Counterfeit medicines 18 3. Quality control — specifi cations and tests 18 3.1 The International Pharmacopoeia (4th edition) 18 3.2 Proposed new work plan 18 3.3 Specifi cations for medicines, including children’s medicines 19 3.4 Revision of texts 21 3.5 General monographs for dosage forms and associated method texts 21 3.6 Radiopharmaceuticals 25 3.7 Dissolution tests for addition to specifi c monographs 26 4. Quality control — International Chemical Reference Substances and International Infrared Reference Spectra 28 4.1 Annual report of the WHO Collaborating Centre 28 4.2 Adoption of new International Chemical
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • B Commission Regulation (Eu)
    02010R0037 — EN — 29.09.2018 — 035.001 — 1 This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document ►B COMMISSION REGULATION (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (Text with EEA relevance) (OJ L 15, 20.1.2010, p. 1) Amended by: Official Journal No page date ►M1 Commission Regulation (EU) No 758/2010 of 24 August 2010 L 223 37 25.8.2010 ►M2 Commission Regulation (EU) No 759/2010 of 24 August 2010 L 223 39 25.8.2010 ►M3 Commission Regulation (EU) No 761/2010 of 25 August 2010 L 224 1 26.8.2010 ►M4 Commission Regulation (EU) No 890/2010 of 8 October 2010 L 266 1 9.10.2010 ►M5 Commission Regulation (EU) No 914/2010 of 12 October 2010 L 269 5 13.10.2010 ►M6 Commission Regulation (EU) No 362/2011 of 13 April 2011 L 100 26 14.4.2011 ►M7 Commission Regulation (EU) No 363/2011 of 13 April 2011 L 100 28 14.4.2011 ►M8 Commission Implementing Regulation (EU) No 84/2012 of 1 L 30 1 2.2.2012 February 2012 ►M9 Commission Implementing Regulation (EU) No 85/2012 of 1 L 30 4 2.2.2012 February 2012 ►M10 Commission Implementing Regulation (EU) No 86/2012 of 1 L 30 6 2.2.2012 February 2012 ►M11 Commission
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Evidence-Based Guidelines for Treating Depressive Disorders with Antidepressants
    JOP0010.1177/0269881115581093Journal of PsychopharmacologyCleare et al. 581093research-article2015 BAP Guidelines Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association Journal of Psychopharmacology 2015, Vol. 29(5) 459 –525 for Psychopharmacology guidelines © The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881115581093 jop.sagepub.com Anthony Cleare1, CM Pariante2 and AH Young3 With expert co-authors (in alphabetical order): IM Anderson4, D Christmas5, PJ Cowen6, C Dickens7, IN Ferrier8, J Geddes9, S Gilbody10, PM Haddad11, C Katona12, G Lewis12, A Malizia13, RH McAllister-Williams14, P Ramchandani15, J Scott16, D Taylor17, R Uher18 and the members of the Consensus Meeting19 Endorsed by the British Association for Psychopharmacology Abstract A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations
    [Show full text]
  • Report Name:Ukraine's Mrls for Veterinary Drugs
    Voluntary Report – Voluntary - Public Distribution Date: November 05,2020 Report Number: UP2020-0051 Report Name: Ukraine's MRLs for Veterinary Drugs Country: Ukraine Post: Kyiv Report Category: FAIRS Subject Report Prepared By: Oleksandr Tarassevych Approved By: Robin Gray Report Highlights: Ukraine adopted several maximum residue levels (MRLs) for veterinary drugs, coccidiostats and histomonostats in food products of animal origin. Ukraine also adopted a list of drugs residues that are not allowed in food products. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY The Office of Agricultural Affairs of USDA/Foreign Agricultural Service in Kyiv, Ukraine prepared this report for U.S. exporters of domestic food and agricultural products. While every possible care was taken in the preparation of this report, information provided may not be completely accurate either because policies have changed since the time this report was written, or because clear and consistent information about these policies was not available. It is highly recommended U.S. exporters verify the full set of import requirements with their foreign customers, who are normally best equipped to research such matters with local authorities, before any goods are shipped. This FAIRS Subject Report accompanies other reports on Maximum, Residue Limits established by Ukraine in 2020. Related reports could be found under the following links: 1.) Ukraine's MRLs for Microbiological Contaminants_Kyiv_Ukraine_04-27-2020 2.) Ukraine's MRLs for Certain Contaminants_Kyiv_Ukraine_03-06-2020 Food Products of animal origin and/or ingredients of animal origin are not permitted in the Ukrainian market if they contain certain veterinary drugs residues in excess of the maximum residue levels established in Tables 1 and 2.
    [Show full text]
  • Pharmacy Prior Authorization Grid ALTCS, and Pharmacy
    Please Note: Refer to the other PA grids for applicable covered services that require PA. PA Grids: Medical, Behavioral Health, Pharmacy Prior Authorization Grid ALTCS, and Pharmacy. (Effective Date of Service 1/1/2021) Injectables that require Prior Authorization All chemotherapeutic drugs must be used for FDA-approved indications and/or in accordance with NCCN guidelines *Indicates prior authorization required if billed charges are greater than $400 PA Required HMO 13 HCPCS Short Description (BUCA- Code SNP) 90378 Respiratory Syncytial Virus Immune Globulin Yes C9036 Patisiran Yes C9047 Caplacizumab-yhdp Yes C9061 Teprotumumab-trbw Yes C9063 Eptinezumab-jjmr Yes C9131 Factor VIII antihemophilic factor pegylated-auci Yes C9132 Prothrombin Complex Concentrate (Human), Kcentra Yes C9133 Factor IX (Antihemophilic Factor, Recombinant), Rixibus Yes C9399 Mipomersen (Kynamro) Yes J0129 Abatacept Yes J0135 Adalimumab Yes J0178 Aflibercept Yes J0179 Brolucizumab-dbll, 1 mg Yes J0180 Agalsidase Beta Yes J0205 Alglucerase Yes J0215 Alefacept Yes J0220 Alglucosidase Alfa (Myozyme) Yes J0221 Alglucosidase Alfa (Lumizyme) Yes J0222 Patisiran, 0.1 mg Yes J0223 Givosiran 0.5 mg Yes J0256 Alpha 1-Proteinase Inhibitor Yes J0257 Alpha 1-Proteinase Inhibitor (Glassia) Yes J0275 Alprostadil Urethral Suppository Yes J0490 Belimumab Yes J0517 Benralizumab Yes J0567 Cerliponase alfa Yes J0570 Buprenorphine implant Yes J0584 Burosumab-twza 1 mg Yes J0585 Onabotulinumtoxina (Botox) Yes J0586 Abobotulinumtoxina (Dysport) Yes J0587 Rimabotulinumtoxinb (Myobloc)
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • A New Venue of TNF Targeting
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 April 2018 doi:10.20944/preprints201804.0015.v1 Peer-reviewed version available at Int. J. Mol. Sci. 2018, 19, 1442; doi:10.3390/ijms19051442 1 Review 2 A new venue of TNF targeting 3 Sophie Steeland1, Claude Libert2 and Roosmarijn E. Vandenbroucke3,* 4 1 Barriers in Inflammation, VIB Center for Inflammation Research, Ghent; Department of Biomedical Molecular 5 Science, Ghent University, Ghent Belgium; [email protected] 6 2 Mouse Genetics in Inflammation, VIB Center for Inflammation Research, Ghent; Department of Biomedical 7 Molecular Science, Ghent University, Ghent Belgium; [email protected] 8 3 Barriers in Inflammation, VIB Center for Inflammation Research, Ghent; Department of Biomedical Molecular 9 Science, Ghent University, Ghent Belgium; [email protected] 10 * Correspondence: [email protected]; Tel.: +32 9 331 35 87 11 Received: date; Accepted: date; Published: date 12 13 Abstract: The first FDA-approved drugs were small, chemically-manufactured and highly active 14 molecules with possible off-target effects. After this first successful wave of small drugs, biotechnology 15 allowed the development of protein-based medicines such as antibodies. Conventional antibodies bind 16 a specific protein and are becoming increasingly important in the therapeutic landscape. A very 17 prominent class of biologicals are the anti-TNF drugs that are applied in several inflammatory diseases 18 that are characterized by dysregulated TNF levels. Marketing of TNF inhibitors revolutionized the 19 treatment of diseases such as Crohn’s disease. However, these inhibitors also have undesired effects, 20 some of them directly associated with the inherent nature of this drug class such as immunogenicity, 21 whereas others are linked with their mechanism of action.
    [Show full text]
  • Kalbitor® (Ecallantide)
    Kalbitor® (ecallantide) (Subcutaneous) Document Number: MODA-0167 Last Review Date: 10/01/2020 Date of Origin: 08/27/2013 Dates Reviewed: 04/2014, 09/2014, 03/2015, 06/2015, 09/2015, 12/2015, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018 10/2018, 10/2019, 03/2020, 10/2020 I. Length of Authorization Coverage will be provided for 12 weeks and is eligible for renewal (unless otherwise specified). The cumulative amount of medication(s) the patient has on-hand, indicated for the acute treatment of HAE, will be taken into account when authorizing. The authorization will provide a sufficient quantity in order for the patient to have a cumulative amount of HAE medication on-hand in order to treat up to 4 acute attacks per 4 weeks for the duration of the authorization (unless otherwise specified). II. Dosing Limits A. Quantity Limit (max daily dose) [NDC unit]: Kalbitor 10 mg vial: 24 vials per 28 days B. Max Units (per dose and over time) [HCPCS Unit]: 240 billable units per 28 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: Patient is at least 12 years of age; AND Universal Criteria 1,13,18 Must be prescribed by, or in consultation with, a specialist in: allergy, immunology, hematology, pulmonology, or medical genetics; AND Confirmation the patient is avoiding the following possible triggers for HAE attacks: o Estrogen-containing oral contraceptive agents AND hormone replacement therapy; AND o Antihypertensive agents containing ACE inhibitors; AND o Dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin); AND o Neprilysin inhibitors (e.g., sacubitril) Moda Health Plan, Inc.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,682,960 B2 Labrie Et Al
    USOO968296OB2 (12) United States Patent (10) Patent No.: US 9,682,960 B2 Labrie et al. (45) Date of Patent: Jun. 20, 2017 (54) NON-STEROIDAL ANTANDROGENS AND (56) References Cited SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH APYRIDYL MOETY U.S. PATENT DOCUMENTS 3,742.951 7, 1973 Zaffaroni (71) Applicants: Fernand Labrie, Quebec (CA); 3,797.494 3, 1974 Zaffaroni Shankar Mohan Singh, Quebec (CA); 4,568,343 2, 1986 Leeper et al. Richard Labrecque, St-Nicolas (CA); 5,064,654 11, 1991 Berner et al. 5,071,644 12, 1991 Viegas et al. Liviu Constantin Ciobanu, Quebec 5,071,657 12, 1991 Oloff et al. (CA) 5,411,981 5, 1995 Gaillard-Kelly et al. 5,556,983 9, 1996 Claussner et al. (72) Inventors: Fernand Labrie, Quebec (CA); 5,750,553 5, 1998 Claussner et al. 6,071,957 6/2000 Miller et al. Shankar Mohan Singh, Quebec (CA); 7/2000 Claussner et al. Richard Labrecque, St-Nicolas (CA); 6,087,509 Liviu Constantin Ciobanu, Quebec (Continued) (CA) FOREIGN PATENT DOCUMENTS (73) Assignee: ENDORECHERCHE, INC. (CA) CA 2 677 295 9, 2008 CA 2 773 591 3, 2011 EP 0 002892 A1 7/1979 (*) Notice: Subject to any disclaimer, the term of this EP O 100 172 A1 2, 1984 patent is extended or adjusted under 35 EP O 279 982 A1 8, 1988 U.S.C. 154(b) by 0 days. EP O 494 819 A1 7, 1992 EP O 578516 A1 1, 1994 Appl. No.: 14/567,970 EP O 580 459 A1 1, 1994 (21) FR 2 671 348 A1 7, 1992 Filed: Dec.
    [Show full text]
  • Biomaterials: a Potential Pathway to Healing Chronic Wounds?
    DR. BENJAMIN DAVID ALMQUIST (Orcid ID : 0000-0001-9718-777X) Received Date : 25-Feb-2016 Revised Date : 17-Nov-2016 Accepted Date : 28-Dec-2016 Article type : Viewpoint Biomaterials: A potential pathway to healing chronic wounds? Mara A Pop1 and Benjamin D Almquist1 1. Department of Bioengineering, Imperial College London, London SW7 2AZ, UK Article Corresponding Author: Benjamin D Almquist Email: [email protected] Declarations: None Key Words: biomaterials, chronic wound, wound healing, diabetic ulcer, tissue repair Abstract Chronic dermal wounds are a devastating problem that disproportionally affect individuals with conditions such as diabetes, paralysis, or simply old age. These wounds are extremely challenging to treat due to a heterogeneous combination of causative factors, creating a This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as Accepted doi: 10.1111/exd.13290 This article is protected by copyright. All rights reserved. substantial burden on healthcare systems worldwide. Despite their large impact, there is currently a startling lack of options for effectively treating the underlying biological changes that occur within the wounds. Biomaterials possess an enticing ability to provide new comprehensive approaches to healing these devastating wounds; advanced wound dressings are now being developed that enable the ability to coordinate temporal delivery of multiple therapeutics, protect sensitive biologics from degradation, and provide supportive matrices that encourage the growth of tissue. This positions biomaterials as a potential ‘conductor’ of wound repair, allowing them to simultaneously address numerous barriers to healing, and in turn providing a promising pathway to innovative new technologies for driving successful healing.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]